Clementia Pharmaceuticals, a clinical stage biotech focused on treating bone diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Montreal, Canada-based company was founded in 2010 and plans to list on the Nasdaq under the symbol CMTA. Morgan Stanley and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
